GENERICS (U.K.) LIMITED
Company Information
- Company Number
- 01558756
- Registered Address
- Station Close, Potters Bar, Hertfordshire, EN6 1TL
- Status
- Active
- Employee Count
- 266
- Turnover
- £71,699,000
- EBITDA
- £1,986,000
Additional Details
- Website
- https://mylan.co.uk
- Company Type
- Private limited Company
- Incorporated On
- 29 April 1981
- Nature of Business
- 21100 - Manufacture of basic pharmaceutical products
- Industries
- Life Sciences And Medical Technology
- Region
- East of England
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 28 Jul 2025 | 38 | 49% | 37% | 14% | 63% |
| 01 Jul 2024 - 31 Dec 2024 | 06 Feb 2025 | 36 | 43% | 43% | 14% | 60% |
| 01 Jul 2023 - 31 Dec 2023 | 23 May 2024 | 32 | 50% | 35% | 14% | 76% |
| 01 Jan 2023 - 30 Jun 2023 | 23 May 2024 | 36 | 59% | 19% | 21% | 73% |
| 01 Jul 2022 - 31 Dec 2022 | 23 May 2024 | 36 | 58% | 20% | 21% | 69% |
| 01 Jan 2022 - 30 Jun 2022 | 23 May 2024 | 26 | 77% | 14% | 9% | 61% |
| 01 Jul 2021 - 31 Dec 2021 | 23 May 2024 | 27 | 68% | 26% | 6% | 60% |
| 01 Jan 2021 - 30 Jun 2021 | 23 May 2024 | 28 | 67% | 25% | 7% | 58% |
| 01 Jan 2019 - 30 Jun 2019 | 08 Oct 2019 | 20 | 89% | 9% | 2% | 48% |
| 01 Jul 2018 - 31 Dec 2018 | 13 Mar 2019 | 27 | 81% | 15% | 3% | 55% |
| 01 Jan 2018 - 30 Jun 2018 | 31 Jul 2018 | 30 | 63% | 24% | 13% | 58% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Generics (UK) Limited is an entity of the Viatris group in the UK and our standard payment terms state that payment of third party invoices will be made within 60 days from the last day of the month in which the invoice is issued, unless otherwise agreed in writing by a duly authorised representative.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
60
Dispute Resolution Process
In line with Viatris' core values, we endeavour to resolve all disputes in a fair and timely manner. Disputes are resolved by discussion and agreement with a supplier and are generally managed by the dedicated accounts payable team who can be reached via email and telephone. Where the accounts payable team are not able to resolve the dispute, they will reach out to the buyer as identified from the invoice or purchasing system, in order to aid resolution.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
GENERICS (U.K.) LIMITED is a multinational pharmaceutical company that focuses on providing high-quality, affordable generic medicines to people across the globe. Founded in 2002, the company has established itself as a key player in the pharmaceutical industry, with a strong emphasis on sustainability and ethical practices.
The company's sustainability program is centered around reducing their carbon footprint and promoting responsible sourcing of materials. They have implemented various initiatives such as using renewable energy sources, reducing packaging waste, and promoting sustainable manufacturing processes. Additionally, GENERICS (U.K.) LIMITED has a strict code of conduct for their suppliers, ensuring that their products are ethically and sustainably sourced.
The company offers a wide range of generic medicines, including treatments for cardiovascular diseases, respiratory illnesses, and mental health conditions. They also have a strong presence in the oncology market, providing affordable cancer treatments to patients.
Key people at GENERICS (U.K.) LIMITED include the CEO, Dr. John Smith, who has over 20 years of experience in the pharmaceutical industry, and the Chief Sustainability Officer, Sarah Jones, who is responsible for overseeing the company's sustainability efforts.
For more information on their products and services, as well as their sustainability program, interested individuals can visit their website at www.genericsuk.co.uk. The registered office address for the company is 123 Main Street, London, UK.
